Madrigal Pharmaceuticals (MDGL) Total Debt (2022 - 2025)
Historic Total Debt for Madrigal Pharmaceuticals (MDGL) over the last 10 years, with Q3 2025 value amounting to $339.8 million.
- Madrigal Pharmaceuticals' Total Debt rose 19017.14% to $339.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $339.8 million, marking a year-over-year increase of 19017.14%. This contributed to the annual value of $117.6 million for FY2024, which is 180.9% up from last year.
- Latest data reveals that Madrigal Pharmaceuticals reported Total Debt of $339.8 million as of Q3 2025, which was up 19017.14% from $118.4 million recorded in Q2 2025.
- In the past 5 years, Madrigal Pharmaceuticals' Total Debt ranged from a high of $339.8 million in Q3 2025 and a low of $48.7 million during Q2 2022
- Its 4-year average for Total Debt is $114.6 million, with a median of $115.8 million in 2023.
- Examining YoY changes over the last 5 years, Madrigal Pharmaceuticals' Total Debt showed a top increase of 19017.14% in 2025 and a maximum decrease of 151.71% in 2025.
- Madrigal Pharmaceuticals' Total Debt (Quarter) stood at $49.3 million in 2022, then surged by 134.29% to $115.5 million in 2023, then grew by 1.81% to $117.6 million in 2024, then soared by 188.98% to $339.8 million in 2025.
- Its last three reported values are $339.8 million in Q3 2025, $118.4 million for Q2 2025, and $118.0 million during Q1 2025.